Release Date: September 30, 2014 | Expiration Date: September 30, 2015
Media: Print with online posttest, evaluation, and request for credit
OverviewAdvanced pancreatic cancer is a devastating disease with few available treatment options that yield very limited survival benefits. Research to improve the outcomes of these patients has resulted in a remarkable increase in the knowledge of the underlying molecular biology and mechanisms of therapy resistance of pancreatic adenocarcinoma. These insights have resulted in the rational development of new formulations of cytotoxic agents and the integration of targeted agents and immunotherapies into therapeutic regimens currently being evaluated in various clinical trials in this difficult to treat malignancy.
Given the limited therapeutic options for patients with advanced pancreatic cancer and the recent advances noted previously, it is important for community oncologists to be educated about these emerging treatments so that they can deliver optimal care to their patients.
If you have read article "Pancreatic Cancer: Novel and Emerging Approaches to Early Detection and Treatment" in the September Issue of AJHO and would like to request credit, click the "Take Post-Test" button below.
Instructions For Receiving Credit
If you have NOT read the article and would like to participant the online CME-certified activity, click the "Start Online Activity" button below.
This activity is directed toward medical oncologists and hematologists who treat patients with solid tumors and hematologic malignancies. Fellows, nurses, physician assistants, nurse practitioners, and other healthcare providers may also participate.
After participating in this CME activity, learners should be better prepared to:
- Describe molecular pathways and targeted therapies with clinical potential in advanced pancreatic cancer
- Review the safety, and efficacy data, and potential clinical role of novel treatment regimens with cytotoxic and/or targeted components
- Recognize and manage adverse events associated with established and novel therapies in pancreatic adenocarcinoma
Disclosure: No relevant financial relationships with commercial interests to disclose.
Debu Tripathy, MD
The American Journal of Hematology/Oncology Editorial Board Member
Professor of Medicine and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Disclosure: Grant/Research Support: Genentech/Roche, Pfizer, Puma, Inc. (clinical trial support contracted to University of Southern California); Consultant: Eisai, Novartis
The staff of PER® (Debbie Augustus, Ann C. Lichti, CCMEP and Megan O'Connell) as well as the Editorial Staff of The American Journal of Hematology/Oncology (Devera Pine) have no relevant financial relationships with commercial interests to disclose.
Staff/Planner Disclosures and Conflict of Interest Resolution
In accordance with ACCME's Standards for Commercial SupportSM, PER® resolved all conflicts of interest (COI) prior to the release of this CME activity using a multistep process.
Accreditation/ Credit DesignationPhysicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial SupportThis activity is funded by Physicians’ Education Resource®.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Hardware And Software Requirements
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise